BACKGROUND AND PURPOSE: Telestroke networks offer an opportunity to increase tissue-type plasminogen activator use in community hospitals. METHODS: We compared 83 patients treated with intravenous tissue-type plasminogen activator by telestroke to 59 patients treated after in-person evaluation by the same neurologists at a tertiary care stroke center. Onset and door-to-treatment times and functional outcome at 90 days were obtained prospectively. Favorable outcome was defined as modified Rankin Scale score ≤2. RESULTS: Favorable outcome rates were comparable between the groups (42.1% versus 37.5%, P=0.7). There was no significant difference in the rate of symptomatic hemorrhage. CONCLUSIONS: Telestroke is a viable alternative to in-person evaluation when stroke expertise is not readily available.
BACKGROUND AND PURPOSE: Telestroke networks offer an opportunity to increase tissue-type plasminogen activator use in community hospitals. METHODS: We compared 83 patients treated with intravenous tissue-type plasminogen activator by telestroke to 59 patients treated after in-person evaluation by the same neurologists at a tertiary care stroke center. Onset and door-to-treatment times and functional outcome at 90 days were obtained prospectively. Favorable outcome was defined as modified Rankin Scale score ≤2. RESULTS: Favorable outcome rates were comparable between the groups (42.1% versus 37.5%, P=0.7). There was no significant difference in the rate of symptomatic hemorrhage. CONCLUSIONS: Telestroke is a viable alternative to in-person evaluation when stroke expertise is not readily available.
Authors: Patricia Martínez-Sánchez; Ambrosio Miralles; Rosa Sanz de Barros; Daniel Prefasi; Borja E Sanz-Cuesta; Blanca Fuentes; Gerardo Ruiz-Ares; Marta Martínez-Martínez; Elena Miñano; Juan José Arévalo-Manso; Elisa Correas-Callero; Andrés Cruz-Herranz; Exuperio Díez-Tejedor Journal: J Neurol Date: 2014-06-24 Impact factor: 4.849
Authors: Shawna Cutting; James J Conners; Vivien H Lee; Sarah Song; Shyam Prabhakaran Journal: Telemed J E Health Date: 2014-06-26 Impact factor: 3.536
Authors: René Handschu; Mateusz Scibor; Martin Nückel; Dirk Asshoff; Barbara Willaczek; Frank Erbguth; Stefan Schwab; Frank Daumann Journal: J Neurol Date: 2014-08-01 Impact factor: 4.849
Authors: Maarten M H Lahr; Gert-Jan Luijckx; Patrick C A J Vroomen; Durk-Jouke van der Zee; Erik Buskens Journal: J Neurol Date: 2012-08-23 Impact factor: 4.849